HDL-related biomarkers after acute ischemic stroke: HDL particle remodeling, HDL-C–based immune–lipid ratios, and clinical interpretation

Abstract Acute ischemic stroke (AIS) induces neurovascular injury and systemic inflammatory and metabolic responses that alter high-density lipoprotein (HDL) particles. HDL-cholesterol (HDL-C) measures cholesterol mass in HDL particles but does not report particle composition or biological function. Ratios using HDL-C as the denominator have emerged as candidate biomarkers, but their biological specificity and clinical meaning remain uncertain. This critical narrative review evaluates three evidence domains: directly measured HDL particle remodeling and function after AIS; HDL-C-based immune–lipid ratios, including monocyte/HDL-C, neutrophil/HDL-C, high-sensitivity C-reactive protein/HDL-C and white blood cell/HDL-C; and thromboinflammatory mechanisms relevant to their interpretation. Human AIS studies report altered cholesterol efflux, paraoxonase-1 activity, HDL particle cargo and antioxidant capacity, but cohorts and assays remain limited. Routine ratios show observational associations with outcomes, yet are epidemiological composites, not functional assays or proof of immune–lipid interaction, and ratio-specific genetic architecture or causality has not been established. Here, serial immune–lipid profiling means repeated, prespecified measurement of leukocyte counts, high-sensitivity C-reactive protein, HDL-C and ratios, whereas direct HDL functional assays constitute a separate research tier and are not validated for routine care. Post-stroke immune–HDL mismatch remains a provisional framework requiring immune activation and directly measured HDL functional impairment. Current clinical and imaging predictors remain indispensable but incompletely capture evolving systemic inflammation and metabolism. HDL-related biomarkers should not replace them; validation requires standardized sampling, external cohorts and reproducible incremental prognostic or decision value beyond established predictors.

Authors

Institutions

Publication Details

Journal
Lipids in Health and Disease
Published
2026-10-15
DOI
https://doi.org/10.1186/s12944-026-03095-x
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

HDL-related biomarkers after acute ischemic stroke: HDL particle remodeling, HDL-C–based immune–lipid ratios, and clinical interpretation

Tahereh Kalantari, Mohammad Ali Takhshid, Afshin Borhani‐Haghighi
Lipids in Health and Disease
Lipoproteins and Cardiovascular Health
article

HDL-related biomarkers after acute ischemic stroke: HDL particle remodeling, HDL-C–based immune–lipid ratios, and clinical interpretation

Tahereh Kalantari, Mohammad Ali Takhshid, Afshin Borhani‐Haghighi
article en

Abstract

Abstract Acute ischemic stroke (AIS) induces neurovascular injury and systemic inflammatory and metabolic responses that alter high-density lipoprotein (HDL) particles. HDL-cholesterol (HDL-C) measures cholesterol mass in HDL particles but does not report particle composition or biological function. Ratios using HDL-C as the denominator have emerged as candidate biomarkers, but their biological specificity and clinical meaning remain uncertain. This critical narrative review evaluates three evidence domains: directly measured HDL particle remodeling and function after AIS; HDL-C-based immune–lipid ratios, including monocyte/HDL-C, neutrophil/HDL-C, high-sensitivity C-reactive protein/HDL-C and white blood cell/HDL-C; and thromboinflammatory mechanisms relevant to their interpretation. Human AIS studies report altered cholesterol efflux, paraoxonase-1 activity, HDL particle cargo and antioxidant capacity, but cohorts and assays remain limited. Routine ratios show observational associations with outcomes, yet are epidemiological composites, not functional assays or proof of immune–lipid interaction, and ratio-specific genetic architecture or causality has not been established. Here, serial immune–lipid profiling means repeated, prespecified measurement of leukocyte counts, high-sensitivity C-reactive protein, HDL-C and ratios, whereas direct HDL functional assays constitute a separate research tier and are not validated for routine care. Post-stroke immune–HDL mismatch remains a provisional framework requiring immune activation and directly measured HDL functional impairment. Current clinical and imaging predictors remain indispensable but incompletely capture evolving systemic inflammation and metabolism. HDL-related biomarkers should not replace them; validation requires standardized sampling, external cohorts and reproducible incremental prognostic or decision value beyond established predictors.

Lipids in Health and Disease
Deakin University (AU), Shiraz University of Medical Sciences (IR)
Good health and well-being
Openalex Percentile: Top 10%
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.